Eric Wittchow Email & Phone Number

Warngau, Bayern, Deutschland

- Leading R&D teams in value-added pharmaceuticals (VAP) and long-acting injectables (LAI).- Strategically managing resources and representing the R&D department across organizational levels- Executing and overseeing transparent project management, maintaining high scientific and qualitative standards for value enhancement.- Collaborating with Business.

Reutlingen, Baden-Württemberg, Deutschland

Lecturing on 'Biocompatibility and Functional Surfaces'

- Consulting in the development and productization of magnesium implants- Experience in alloy development, process chain optimization, determination of biological safety, biocompatibility and degradation kinetics to customized GLP-compliant preclinical testing- Development and application of state of the art analytical methods and imaging modalities to.

Lüneburg

• Execute multiple high-quality, complex, cross-functional project including development plans, schedules, milestones, budgets, risks, issues and resources to meet project goals; incorporate technical, resource.
• Coordinate project activities beginning with supply of raw material, prototyping, processing, material and functional analyses, biological safety evaluation, preclinical testing and clinical application
• See product through all phases of the product development lifecycle
• Ensure that final device concepts and prototypes are fulfilling user requirements and end-user needs
• Serve as technical leader for biodegradable materials, local drug delivery and biological interactions of implants, keeping current on clinical trends, the technology and competitors
• Maintain knowledge of ISO, RA regulations (new MDR, FDA, other) and QM system impact on design, project work and documentation (DHF, TF, DIDOV, V&V, FMEA)

Gaithersburg

• Directed day-to-day preclinical and translational research services
• Oversaw design, execution and analysis for various research facilities and educational activities
• Streamlined working process of the institution to further its goal of pre-eminence in the field of cardiovascular research

Bülach, Schweiz

• Set up preclinical study group from the scratch
• Provided leadership in growing the preclinical team through recruiting top academic talent, managing and mentoring preclinical team members and leading them to help drive R&D projects that fulfilled company objectives.
• Pharmacokinetic testing in animals
• Provided independent analysis, evaluation, interpretation and presentation of preclinical results involving a network with external specialists and clinical KOLs
• Developed and verified hypotheses regarding performance of vascular implants and correlate bench test results with preclinical data (IVIVC)
• Supported CE and FDA approval processes with relevant regulatory documents (ISO 13485, ISO 10993 series, ISO 14971, MDD)

Hamburg Und Umgebung, Deutschland

• Conducted phase-IV clinical studies for immunosuppressive drugs
• Consulted and supported sales force in medical questions
• Collected information regarding competitor strategies and therapy optimization programs

Hamburg Und Umgebung, Deutschland

• Raised market share of Intron A (Interferon) from 47% (1998) to 73% (2001)
• Established premarketing activities and introduced dual therapy for hepatitis B+C therapy
• Built network of clinical specialists and KOLs
• Initiated phase-IV clinical studies and monitored phase-III clinical studies

Essen Und Umgebung, Deutschland

• Worked with products for pediatrics, surgery and oncology